Anka G. Ehrhardt
Leader
Bristol-Myers Squibb, New Jersey
USA
Biography
BioPharma research, currently working in the United States for Bristol-Myers Squibb. Before this, she headed a technology laboratory at Merck, covering comprehensive instrumentation in high tech fields such as fluorescence, imaging, flow cytometry, electrophysiology and luminescence for the entire range from early discovery to late stage clinical trials across all disease areas. In her current position at BMS, Dr. Ehrhardt directs the Clinical Cytometry team, covering a large portfolio of immunology, immuno-oncology, and other disease area exploratory and clinical studies. Her work focuses on the strategy and practicalities of biomarkers as tools to drive the development of urgently needed new medicines. This reaches form securing that biomarker assays are optimized to gather clear data in support of fast well founded decision making to systematically maximizing the information gathered from clinical samples to support hypothesis generation. Dr. Ehrhardt is currently on the board of different industry organizations, fostering innovation and collaboration between industry, academia and government organizations.
Research Interest
Immunology and Immuno-oncology